Owens & Minor, Inc.

KENT, Wash.--( BUSINESS WIRE )--Performance Home Medical (“PHM” or the “Company”), a home medical equipment and respiratory services provider, today announced that Larry Mastrovich, who has served as PHM Chairman since January 2024, has been named Chief Executive Officer. Mr. Mastrovich’s appointment follows healthcare-focused private equity firm Grant Avenue Capital’s investment in PHM and reflects PHM’s continued focus on expanding its geographic footprint, bolstering its team with top talent, and accelerating the business’ growth. A seasoned healthcare industry executive, Mr. Mastrovich brings three decades of leadership, operations, sales and marketing, and strategic transaction experience to PHM. For more than 25 years, Mr. Mastrovich worked at Apria Healthcare, the largest home care provider of respiratory products, oxygen therapy, ventilation, CPAP machines and home infusion therapy in the U.S., most recently as President and COO. Prior to joining PHM, he served as President and CEO of Breathe Technologies, a medical device manufacturer for respiratory products specializing in ventilation and sleep apnea solutions. “ The home medical equipment market plays a crucial role in shifting the site of care to the home, when clinically appropriate and beneficial to the patient,” said Brian Berkin, Partner at Grant Avenue Capital. “ Although over 30 million Americans have sleep apnea, only a portion are diagnosed and receiving care. We are confident that under Larry’s leadership, PHM will be well-positioned to grow its access to patients who are out of reach from home-based solutions today.” “ I am excited to step into the CEO role at this pivotal point in PHM’s evolution,” added Mr. Mastrovich. “ PHM has served its core sleep apnea patient base meaningfully for over two decades, and I look forward to building upon this foundation to continue improving outcomes while supporting patients to address chronic care disease management. With the support of the talented PHM team and Grant Avenue, we will continue to expand the business across new geographies, products, and services.” Eric Kim, Principal at Grant Avenue Capital, concluded, “ We are pleased to partner with Larry, who brings a wealth of experience in scaling differentiated healthcare businesses. We look forward to working closely with him and the entire PHM team as we continue to support the Company’s organic growth efforts, add-on acquisitions, and investments in technology.” About Performance Home Medical Founded in 2001, Performance Home Medical (PHM) provides critical home care services to patients in need of obstructive sleep apnea, oxygen, ventilator, and continuous glucose monitoring device and supply needs. Serving over 70,000 patients primarily in the Pacific Northwest, PHM provides reliable access to in-home equipment and supplies throughout its 20+ locations across Washington, Oregon, and Idaho. For more information, please visit https://www.performancehomemed.com/ . About Grant Avenue Capital, LLC Grant Avenue is a healthcare-focused, middle-market private equity firm targeting investments alongside forward-thinking management teams that seek an experienced and innovative investor with highly flexible capital, both in terms of duration and structure. The firm typically invests in companies generating approximately $5 million to $25 million of EBITDA, with the ability to complete larger transactions through strategic co-invest relationships. The firm focuses on control buyouts, buy-and-builds, corporate carve-outs, joint-control partnership investments, and special situations. In addition, the Grant Avenue Foundation supports employees and portfolio companies of Grant Avenue that are actively engaged with healthcare-oriented charitable organizations. For more information, please visit www.grantave.com .

Gross Margin Expansion of 79 Basis Points Adjusted EPS Growth of Nearly Four Times with GAAP EPS Loss of $(0.29) and Adjusted EPS of $0.19 Investments Outlined at 2023 Investor Day for Long-Term Growth are Ahead of Plan RICHMOND, Va.--(BUSINESS WIRE)-- Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the first quarter ended March 31, 2024. Key Highlights: Consolidated revenue of $2.6 billion in the first quarter, representing year-over-year growth of 4% GAAP operating margin was flat while adjusted operating margin expanded by 31 basis points versus prior year Net loss per share of $(0.29) and adjusted earnings per share of $0.19 in the first quarter “Our solid performance in the first quarter was in line with our expectations, as we delivered top-line growth in both segments, adjusted operating margin expansion, and improved year-over-year profitability. At the same time, we are making the kind of investments consistent with our strategic plan previewed at our Investor Day in December 2023,” said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor. “In our Products & Healthcare Services segment, we onboarded new customers, grew same store sales, and invested in inventory to support our new wins and provide best-in-class service levels. On the heels of double-digit growth in the prior years, our Patient Direct segment delivered mid-single digit top-line growth while navigating the unique challenges that occurred in the quarter, demonstrating the strength of our team and the effectiveness of our go-to-market strategies,” concluded Mr. Pesicka. Financial Summary (1) ($ in millions, except per share data) 1Q24 1Q23 Revenue $2,613 $2,523 Operating income, GAAP $9.7 $9.8 Adj. Operating Income, Non-GAAP $57.4 $47.7 Net loss, GAAP $(21.9) $(24.4) Adj. Net Income, Non-GAAP $14.9 $3.6 Adj. EBITDA, Non-GAAP $116.3 $108.7 Net loss per common share, GAAP $(0.29) $(0.32) Adj. Net Income per share, Non-GAAP $0.19 $0.05 (1) Reconciliations of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are included in the tables below. Results and Business Highlights Consolidated revenue of $2.6 billion in the first quarter of 2024, an increase of 4% as compared to the first quarter of 2023 Patient Direct revenue of $638 million, up 5% compared to the first quarter of 2023 Products & Healthcare Services revenue of nearly $2 billion, up 3% compared to the first quarter of 2023 First quarter 2024 operating income of $10 million and Adjusted Operating Income of $57 million On a GAAP basis operating income margins remain flat while adjusted operating income margin expanded by 31 basis points Adjusted operating income of $57.4 million, up 20% compared to the prior year Both Products & Healthcare Services and Patient Direct delivered increases in Segment Income year-over-year 2024 Financial Outlook The Company’s most recent financial guidance; summarized below: Revenue for 2024 to be in a range of $10.5 billion to $10.9 billion Adjusted EBITDA for 2024 to be in a range of $550 million to $590 million Adjusted EPS for 2024 to be in a range of $1.40 to $1.70 The Company’s outlook for 2024 contains assumptions, including current expectations regarding the impact of general economic conditions, including inflation, and the continuation of pressure on pricing and demand in our Products & Healthcare Services segment. Key assumptions supporting the Company’s 2024 financial guidance include: Gross margin rate of 21.0% to 21.5% Interest expense of $141 to $146 million Adjusted effective tax rate of 27.5% to 28.5% Diluted weighted average shares of ~78.5 million Capital expenditures of $220 to $240 million Stable commodity prices FX rates as of 12/31/2023 Although the Company does provide guidance for adjusted EBITDA and adjusted EPS (which are non-GAAP financial measures), it is not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP without unreasonable effort. Certain elements of the composition of the GAAP amounts are not predictable, making it impracticable for the Company to forecast. Such elements include, but are not limited to, restructuring and acquisition charges, which could have a significant and unpredictable impact on our GAAP results. As a result, no GAAP guidance or reconciliation of the Company’s adjusted EBITDA guidance or adjusted EPS guidance is provided. The outlook is based on certain assumptions that are subject to the risk factors discussed in the Company’s filings with the SEC. Investor Conference Call for First Quarter 2024 Financial Results Owens & Minor executives will host a conference call for investors and analysts on Friday, May 3, 2024, at 8:30 a.m. ET. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above. Safe Harbor This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This release contains certain ''forward-looking'' statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our 2024 financial performance, our Operating Model Realignment Program and other cost-saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of its business, including the results of our Operating Model Realignment Program and our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 20, 2024, including the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at . Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. About Owens & Minor Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram. *Registered Trademark or Trademark of O&M Halyard or its affiliates. Owens & Minor, Inc. Consolidated Statements of Operations (unaudited) (dollars in thousands, except per share data) Three Months Ended March 31, 2024 2023 Net revenue $ 2,612,680 $ 2,522,849 Cost of goods sold 2,077,151 2,025,542 Gross profit 535,529 497,307 Distribution, selling and administrative expenses 477,613 448,722 Acquisition-related charges and intangible amortization 20,313 22,188 Exit and realignment charges, net 27,356 15,674 Other operating expense, net 551 916 Operating income 9,696 9,807 Interest expense, net 35,655 42,198 Other expense, net 1,153 1,387 Loss before income taxes (27,112 ) (33,778 ) Income tax benefit (5,226 ) (9,360 ) Net loss $ (21,886 ) $ (24,418 ) Net loss per common share: Basic $ (0.29 ) $ (0.32 ) Diluted $ (0.29 ) $ (0.32 ) Owens & Minor, Inc. Condensed Consolidated Balance Sheets (unaudited) (dollars in thousands) March 31, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 244,866 $ 243,037 Accounts receivable, net of allowances of $7,005 and $7,861 669,861 598,257 Merchandise inventories 1,144,597 1,110,606 Other current assets 177,020 150,890 Total current assets 2,236,344 2,102,790 Property and equipment, net of accumulated depreciation and amortization of $546,326 and $546,397 501,385 543,972 Operating lease assets 349,984 296,533 Goodwill 1,635,368 1,638,846 Intangible assets, net 342,593 361,835 Other assets, net 142,319 149,346 Total assets $ 5,207,993 $ 5,093,322 Liabilities and equity Current liabilities Accounts payable $ 1,218,817 $ 1,171,882 Accrued payroll and related liabilities 79,480 116,398 Current portion of long-term debt 207,658 206,904 Other current liabilities 427,136 396,701 Total current liabilities 1,933,091 1,891,885 Long-term debt, excluding current portion 1,946,005 1,890,598 Operating lease liabilities, excluding current portion 276,327 222,429 Deferred income taxes, net 34,437 41,652 Other liabilities 123,265 122,592 Total liabilities 4,313,125 4,169,156 Total equity 894,868 924,166 Total liabilities and equity $ 5,207,993 $ 5,093,322 Owens & Minor, Inc. Consolidated Statements of Cash Flows (unaudited) (dollars in thousands) Three Months Ended March 31, 2024 2023 Operating activities: Net loss $ (21,886 ) $ (24,418 ) Adjustments to reconcile net loss to cash provided by operating activities: Depreciation and amortization 74,095 70,926 Share-based compensation expense 6,866 6,463 Provision (benefit) for losses on accounts receivable 181 (521 ) Loss on extinguishment of debt — 564 Deferred income tax benefit (3,659 ) (591 ) Changes in operating lease right-of-use assets and lease liabilities 1,139 (225 ) Gain on sale and dispositions of property and equipment (15,619 ) (8,269 ) Changes in operating assets and liabilities: Accounts receivable (75,144 ) 5,240 Merchandise inventories (35,412 ) 45,832 Accounts payable 52,926 23,082 Net change in other assets and liabilities (39,617 ) 36,483 Other, net 3,168 3,832 Cash (used for) provided by operating activities (52,962 ) 158,398 Investing activities: Additions to property and equipment (45,997 ) (46,150 ) Additions to computer software (3,411 ) (5,340 ) Proceeds from sale of property and equipment 49,538 17,306 Other (2,000 ) — Cash used for investing activities (1,870 ) (34,184 ) Financing activities: Borrowings under amended Receivables Financing Agreement 205,000 232,100 Repayments under amended Receivables Financing Agreement (139,300 ) (328,100 ) Repayments of term loans (4,625 ) (26,500 ) Other, net (7,755 ) (4,989 ) Cash provided by (used for) financing activities 53,320 (127,489 ) Effect of exchange rate changes on cash, cash equivalents and restricted cash (618 ) 284 Net decrease in cash, cash equivalents and restricted cash (2,130 ) (2,991 ) Cash, cash equivalents and restricted cash at beginning of period 272,924 86,185 Cash, cash equivalents and restricted cash at end of period(1) $ 270,794 $ 83,194 Supplemental disclosure of cash flow information: Income taxes paid, net $ 2,365 $ 2,405 Interest paid $ 18,211 $ 32,536 Noncash investing activity: Unpaid purchases of property and equipment and computer software at end of period $ 69,368 $ 64,658 (1) Restricted cash as of March 31, 2024 and December 31, 2023 was $25.9 million and $29.9 million and, includes amounts held in an escrow account as required by the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Bundled Payments for Care Improvement (BPCI) initiatives related to wind-down costs of Fusion5, as well as restricted cash deposits received under the Master Receivables Purchase Agreement to be remitted to a third-party financial institution. Owens & Minor, Inc. Summary Segment Information (unaudited) (dollars in thousands) Three Months Ended March 31, 2024 2023 % of % of consolidated consolidated Amount net revenue Amount net revenue Net revenue: Products & Healthcare Services $ 1,974,837 75.6 % $ 1,915,489 75.9 % Patient Direct 637,843 24.4 % 607,360 24.1 % Consolidated net revenue $ 2,612,680 100.0 % $ 2,522,849 100.0 % % of segment % of segment Operating income: net revenue net revenue Products & Healthcare Services $ 11,486 0.58 % $ 1,820 0.10 % Patient Direct 45,879 7.19 % 45,849 7.55 % Acquisition-related charges and intangible amortization (20,313 ) (22,188 ) Exit and realignment charges, net (27,356 ) (15,674 ) Consolidated operating income $ 9,696 $ 9,807 Depreciation and amortization: Products & Healthcare Services $ 23,366 $ 18,566 Patient Direct 50,729 52,360 Consolidated depreciation and amortization $ 74,095 $ 70,926 Capital expenditures: Products & Healthcare Services $ 8,250 $ 6,332 Patient Direct 41,158 45,158 Consolidated capital expenditures $ 49,408 $ 51,490 Owens & Minor, Inc. Net Loss Per Common Share (unaudited) (dollars in thousands, except per share data) Three Months Ended March 31, 2024 2023 Net loss $ (21,886 ) $ (24,418 ) Weighted average shares outstanding - basic 76,319 75,177 Dilutive shares — — Weighted average shares outstanding - diluted 76,319 75,177 Net loss per common share: Basic $ (0.29 ) $ (0.32 ) Diluted $ (0.29 ) $ (0.32 ) Share-based awards for the three months ended March 31, 2024 and 2023 of approximately 1.6 million and 1.7 million shares were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive. Owens & Minor, Inc. GAAP/Non-GAAP Reconciliations (unaudited) (dollars in thousands, except per share data) The following table provides a reconciliation of reported operating income, net loss and net loss per common share to non-GAAP measures used by management. Three Months Ended March 31, 2024 2023 Operating income, as reported (GAAP) $ 9,696 $ 9,807 Acquisition-related charges and intangible amortization (1) 20,313 22,188 Exit and realignment charges, net (2) 27,356 15,674 Operating income, adjusted (non-GAAP) (Adjusted Operating Income) $ 57,365 $ 47,669 Operating income as a percent of net revenue (GAAP) 0.37 % 0.39 % Adjusted operating income as a percent of net revenue (non-GAAP) 2.20 % 1.89 % Net loss, as reported (GAAP) $ (21,886 ) $ (24,418 ) Pre-tax adjustments: Acquisition-related charges and intangible amortization (1) 20,313 22,188 Exit and realignment charges, net (2) 27,356 15,674 Other (3) 430 1,129 Income tax benefit on pre-tax adjustments (4) (11,348 ) (10,977 ) Net income, adjusted (non-GAAP) (Adjusted Net Income) $ 14,865 $ 3,596 Net loss per common share, as reported (GAAP) $ (0.29 ) $ (0.32 ) After-tax adjustments: Acquisition-related charges and intangible amortization (1) 0.20 0.21 Exit and realignment charges, net (2) 0.28 0.15 Other (3) — 0.01 Net income per common share, adjusted (non-GAAP) (Adjusted EPS) $ 0.19 $ 0.05 Owens & Minor, Inc. GAAP/Non-GAAP Reconciliations (unaudited), continued (dollars in thousands) The following tables provide reconciliations of net loss and total debt to non-GAAP measures used by management. Three Months Ended March 31, 2024 2023 Net loss, as reported (GAAP) $ (21,886 ) $ (24,418 ) Income tax benefit (5,226 ) (9,360 ) Interest expense, net 35,655 42,198 Acquisition-related charges and intangible amortization (1) 20,313 22,188 Exit and realignment charges, net (2) 27,356 15,674 Other depreciation and amortization (5) 48,014 49,991 Stock compensation (6) 6,176 6,350 LIFO charges (7) 5,438 4,940 Other (3) 430 1,129 Adjusted EBITDA (non-GAAP) $ 116,270 $ 108,692 March 31, December 31, 2024 2023 Total debt, as reported (GAAP) $ 2,153,663 $ 2,097,502 Cash and cash equivalents (244,866 ) (243,037 ) Net debt (non-GAAP) $ 1,908,797 $ 1,854,465 The following items have been excluded in our non-GAAP financial measures: (1) Acquisition-related charges and intangible amortization includes no acquisition-related charges for the three months ended March 31, 2024 and $1.3 million in acquisition-related charges for the three months ended March 31, 2023, as well as amortization of intangible assets established during acquisition method of accounting for business combinations. Acquisition-related charges consist primarily of one-time costs related to the acquisition of Apria, Inc., including transaction costs necessary to consummate the acquisition, which consisted of investment banking advisory fees and legal fees and director and officer tail insurance expense, as well as transition costs, such as severance and retention bonuses, information technology (IT) integration costs and professional fees. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results. (2) During the three months ended March 31, 2024, exit and realignment charges, net were $27.4 million. These charges primarily related to our (1) Operating Model Realignment Program of $33.5 million, including professional fees, severance, and other costs to streamline functions and processes and (2) costs related to IT strategic initiatives such as converting certain divisions to common IT systems of $1.2 million partially offset by (3) a $7.4 million gain on the sale of our corporate headquarters. During the three months ended March 31, 2023, exit and realignment charges, net consisted of severance, professional, and other fees primarily associated with our Operating Model Realignment Program. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis. (3) For the three months ended March 31, 2024 and 2023, other includes interest costs and net actuarial losses related to our frozen noncontributory, unfunded retirement plan for certain retirees in the United States (U.S.). Additionally, for the three months ended March 31, 2023, other includes loss on extinguishment of debt for the write-off of deferred financing costs of $0.6 million associated with early principal payments. (4) These charges have been tax effected by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes. (5) Other depreciation and amortization relates to property and equipment and capitalized computer software, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges. (6) Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges. (7) LIFO charges includes non-cash adjustments to merchandise inventories valued at the lower of cost or market, with the approximate cost determined by the last-in, first-out (LIFO) method for distribution inventories in the U.S. within our Products & Healthcare Services segment. Use of Non-GAAP Measures This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, the measures exclude items and charges that (i) management does not believe reflect Owens & Minor, Inc.’s (the Company) core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate the Company’s performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation. Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company’s performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated. OMI-CORP OMI-IR View source version on businesswire.com: Contacts Investors Alpha IR Group Jackie Marcus or Nick Teves OMI@alpha-ir.com Jonathan Leon SVP Finance & Treasurer Investor.Relations@owens-minor.com Media Stacy Law media@owens-minor.com Source: Owens & Minor, Inc. View this news release online at:

Healthcare Providers and Suppliers Recognized for Commitment to Digital-First Supply Chains LOUISVILLE, Colo., April 9, 2024 /PRNewswire/ -- Global Healthcare Exchange (GHX) today proudly named 89 leading healthcare provider and supplier organizations to the 2023 Millennium Club. The Millennium Club honors healthcare organizations that demonstrate their commitment to a digital-first supply chain by automating more than one million transactions annually through the GHX Exchange, an industry leading cloud-based supply chain network. Honorees were selected from more than 5,300 healthcare providers and suppliers in North America who embraced the strong role of digitalization in improving patient care and lowering the cost to deliver it. "Supply chain automation goes far beyond enhancing operational efficiency—it plays a vital role in driving the levels of agility and resilience required for the modern healthcare enterprise—and it lies at the heart of the digital transformation that is shaping how and where care is delivered," said Tina Vatanka Murphy, president and CEO, GHX. "In an era where the call for operational excellence and sustainability within healthcare is louder and more urgent than ever, the achievements of the 2023 Millennium Club stand as a testament to what is possible when technology and visionary leadership converge." Millennium Club members will be celebrated at the 2024 GHX Summit taking place May 13-16 at the JW Marriott in Austin, Texas. The Summit will further highlight the advancements and collaborative endeavors within the healthcare supply chain, fostering discussions aimed at propelling the industry toward greater innovation and efficiency. The 2023 GHX Millennium Club includes: Providers: AdventHealth (Altamonte Springs, Fla.) Advocate Aurora Health Inc. (Milwaukee, Wis.) Ardent Health (Brentwood, Tenn.) Alberta Health Services (Edmonton, Alberta) Allina Health (Minneapolis, Minn.) Ascension Health (St. Louis, Mo.) Banner Health (Tucson, Ariz.) Beth Israel Lahey Health (Cambridge, Mass.) Bon Secours Mercy Health (Cincinnati, Ohio) Centura Health (Englewood, Colo.) Christus Health (Dallas, Texas) The Cleveland Clinic Foundation (Cleveland, Ohio) CommonSpirit Health (Englewood, Colo.) Community Health Systems (Franklin, Tenn.) Corewell Health (Grand Rapids, Mich.) Endeavor Health (Evanston, Ill.) Hackensack Meridian Health (Edison, N.J.) HCA Healthcare (Nashville, Tenn.) Henry Ford Health (Detroit, Mich.) LifePoint Health (Brentwood, Tenn.) M Health Fairview (Minneapolis, Minn.) Medical University Hospital Authority (Charleston, S.C.) MedStar Health (Nottingham, Md.) Memorial Hermann Health System (Houston, Texas) Mohawk Medbuy Corporation (Burlington, Ont.) Montefiore Health System (Tarrytown, N.Y.) Mount Sinai Health System (New York, N.Y.) MultiCare Health System (Tacoma, Wash.) NewYork-Presbyterian (New York, N.Y.) Northwell Health (New Hyde Park, N.Y.) NYU Langone Health (New York, N.Y.) Ochsner Health (New Orleans, La.) OhioHealth Corp (Columbus, Ohio) The Ohio State University (Columbus, Ohio) Piedmont Healthcare (Atlanta, Ga.) Providence Health and Services (Renton, Wash.) RWJ Barnabas Health (West Orange, N.J.) Scripps Health (San Diego, Calif.) Sentara Healthcare (Norfolk, Va.) Mercy (Chesterfield, Mo.) SSM Health (Saint Louis, Mo.) Stanford Health Care (Stanford, Calif.) Sutter Health (Roseville, Calif.) Houston Methodist (Houston, Texas) UNC Health (Chapel Hill, N.C.) Trinity Health System (Livonia, Mich.) UC Health (Aurora, Colo.) UCSF Health (San Francisco, Calif.) UnityPoint Health (West Des Moines, Iowa) Universal Health Services, Inc. (King of Prussia, Penn.) UVA Health (Charlottesville, Va.) West Virginia University Health System (Morgantown, W. Va.) Yale New Haven Health System (New Haven, Conn.) Suppliers: 3M Company (St. Paul, Minn.) Abbott Laboratories (Chicago, Ill.) B. Braun Medical Inc. (Bethlehem, Penn.) Baxter International Inc. (Deerfield, Ill.) Becton, Dickinson and Company (Franklin Lakes, N.J.) Boston Scientific Corporation (Marlborough, Mass.) Cardinal Health (Dublin, Ohio) CDW Corporation (Chicago, Ill.) Cencora (Conshohocken, Penn.) Concordance Healthcare Solutions (Tiffin, Ohio) Cook Medical LLC (Bloomington, Ind.) DH Business Services (Washington. D.C.) Edwards Lifesciences Corp. (Irvine, Calif.) GE HealthCare Technologies, Inc. (Chicago, Ill.) Henry Schein, Inc. (Melville, N.Y.) Integra Lifesciences Corporation (Princeton, N.J.) Intuitive Surgical (Sunnyvale, Calif.) Johnson & Johnson (New Brunswick, N.J.) McKesson Corporation (Irving, Texas) Medline Industries, Inc. (Northfield, Ill.) Medtronic (Minneapolis, Minn.) Merit Medical - North America (South Jordan, Utah) ODP Business Solutions (Boca Raton, Fla.) Olympus Corporation of the Americas (Center Valley, Penn.) Owens & Minor, Inc. (Mechanicsville, Va.) Performance Health (Akron, Ohio) Siemens Healthineers (Issaquah, Wash.) Smith+Nephew (Andover, Mass.) Staples (Framingham, Mass.) STERIS (Mentor, Ohio) Stryker Corporation (Kalamazoo, Mich.) Teleflex Incorporated (Morrisville, N.C.) Terumo Americas Holding, Inc. (Somerset, N.J.) Thermo Fisher Scientific (Waltham, Mass.) W.W. Grainger, Inc. (Lake Forest, Ill.) Zimmer Biomet (Warsaw, Ind.) About GHX Building on decades of collaboration among providers, manufacturers, distributors and other industry stakeholders, Global Healthcare Exchange, LLC (GHX) is leading the charge in helping organizations run the new business of healthcare. By automating key business processes and translating evidence-based analytics and data into meaningful action, GHX is helping the healthcare ecosystem to move faster, operate more intelligently and achieve greater outcomes. With the support of GHX, healthcare organizations have removed billions of dollars of wasteful healthcare spend. For more information on GHX's suite of cloud-based supply chain solutions, visit and The Healthcare Hub. CONTACT: Eileen Flynn [email protected] SOURCE Global Healthcare Exchange (GHX)